Randomized multicenter phase III study of a modified docetaxel and cisplatin plus fluorouracil regimen compared with cisplatin and fluorouracil as first-line therapy for advanced or locally recurrent gastric cancer

• Published in: Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association Vol. 19; no. 1; pp. 234 - 244
• Main Authors: Wang, Jinwan, Xu, Ruihua, Li, Jian, Bai, Yuxian, Liu, Tianshu, Jiao, Shunchang, Dai, Guanghai, Xu, Jianming, Liu, Yunpeng, Fan, Nanfeng, Shu, Yongqian, Ba, Yi, Ma, Dong, Qin, Shukui, Zheng, Leizhen, Chen, Weichang, Shen, Lin
• Format: Journal Article
• Language: English
• Published: Tokyo Springer Japan 01.01.2016; Springer Nature B.V
• Subjects: Abdominal Surgery; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols - adverse effects; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Cancer Research; Cisplatin - administration & dosage; Cisplatin - adverse effects; Female; Fluorouracil - administration & dosage; Fluorouracil - adverse effects; Gastric cancer; Gastroenterology; Humans; Male; Medicine; Medicine & Public Health; Middle Aged; Neoplasm Recurrence, Local; Oncology; Original; Original Article; Stomach Neoplasms - drug therapy; Stomach Neoplasms - mortality; Stomach Neoplasms - pathology; Surgical Oncology; Survival Rate; Taxoids - administration & dosage; Taxoids - adverse effects; Treatment Outcome; Young Adult; Safety; Overall survival; Advanced gastric cancer; Progression-free survival; Modified docetaxel and cisplatin plus fluorouracil regimen
• DOI: 10.1007/s10120-015-0457-4
• ISSN: 1436-3291; 1436-3305

Background The V325 study showed that docetaxel, cisplatin, and fluorouracil (DCF) prolonged overall survival (OS) of patients with advanced gastric cancer, but with a high incidence of dose-limiting toxicities. We investigated the efficacy and safety of a modified DCF (mDCF) regimen for Chinese patients with advanced gastric cancer. Methods Untreated advanced gastric cancer patients randomly received docetaxel and cisplatin at 60 mg/m 2 (day 1) followed by fluorouracil at 600 mg/m 2 /day (days 1–5; mDCF regimen) or cisplatin at 75 mg/m 2 (day 1) followed by fluorouracil at 600 mg/m 2 /day (days 1–5; CF) every 3 weeks. The primary end point was progression-free survival (PFS). The secondary end points were OS, overall response rate (ORR), time-to-treatment failure (TTF), and safety. Results In total, 243 patients were randomized to treatment (mDCF regimen 121; CF 122). Compared with CF, the mDCF regimen significantly improved PFS and OS: the median PFS was 7.2 and 4.9 months, respectively [hazard ratio (HR) 0.58, log-rank P  = 0.0008], and the median OS was 10.2 and 8.5 months, respectively (HR = 0.71, P  = 0.0319). Additionally, the mDCF regimen improved the parameters used as secondary objectives: the ORR was 48.7 % with the mDCF regimen versus 33.9 % with CF ( P  = 0.0244); the median TTF was 3.4 months with the mDCF regimen and 2.4 months with CF (HR = 0.67, P  = 0.0027). Grade 3 and grade 4 treatment-related adverse events occurred in 77.3 % of patients who received the mDCF regimen versus 46.1 % of patients who received CF ( P  < 0.001). Conclusions The mDCF regimen, compared with CF, significantly prolonged PFS and OS and enhanced ORR of Chinese patients with advanced gastric cancer. The mDCF regimen achieved efficacy comparable to that of DCF but with fewer toxicities, which is appropriate for the Chinese population.